Data from first cohort of five participants suggest an acceptable safety profile for AB-1003 in participants with limb-girdle muscular dystrophy (LGMD) 2I/R9, with no dose-limiting toxicities or ...
AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced it will present initial safety data from the first cohort of participants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback